The three-decade long journey in heart failure drug development
KS Lewis, J Butler, J Bauersachs, P Sandner - Heart Failure, 2017 - Springer
Heart failure is a global disease with increasing prevalence due to an aging worldwide
population with increasing co-morbidities. Despite several therapeutic options available to …
population with increasing co-morbidities. Despite several therapeutic options available to …
Ischemic left ventricle systolic dysfunction: an evidence-based approach in diagnostic tools and therapeutics
EG Lima, FPC Carvalho, JPP Linhares Filho… - Revista da Associação …, 2017 - SciELO Brasil
Coronary artery disease (CAD) associated with left ventricular systolic dysfunction is a
condition related to poor prognosis. There is a lack of robust evidence in many aspects …
condition related to poor prognosis. There is a lack of robust evidence in many aspects …
The effect of candesartan on pentraxin-3 plasma levels as marker of endothelial dysfunction in patients with essential arterial hypertension
V Buda, M Andor, C Cristescu, M Voicu… - Irish Journal of Medical …, 2017 - Springer
Background In the last decades, the studies performed on the field of endothelial dysfunction
confirmed the fact that the starting point of this pathology is the inflammation. Several …
confirmed the fact that the starting point of this pathology is the inflammation. Several …
Liguzinediol enhances the inotropic effect of rat hearts via inhibition of protein phosphatase (PP1 and PP2A) activities
S Li, H Huang, M Zhang, W Wang, S Xue… - Journal of …, 2017 - journals.lww.com
It has been demonstrated that liguzinediol (2, 5-dihydroxymethyl-3, 6-dimethylpyrazine,
LZDO), a derivative of ligustrazine from Ligusticum wallichii Franch, exerts positive inotropy …
LZDO), a derivative of ligustrazine from Ligusticum wallichii Franch, exerts positive inotropy …
Elastase‐2, an angiotensin II‐generating enzyme, contributes to increased angiotensin II in resistance arteries of mice with myocardial infarction
Background and Purpose Angiotensin II (Ang II), whose generation largely depends on
angiotensin‐converting enzyme (ACE) activity, mediates most of the renin‐angiotensin …
angiotensin‐converting enzyme (ACE) activity, mediates most of the renin‐angiotensin …
A review of chemical therapies for treating diabetic hypertension
PA Sarafidis, ME Alexandrou… - Expert opinion on …, 2017 - Taylor & Francis
Introduction: Hypertension and diabetes are two of the most important modifiable risk factors
for cardiovascular and renal disease. The majority of patients with diabetes also have high …
for cardiovascular and renal disease. The majority of patients with diabetes also have high …
[PDF][PDF] Tratamento farmacológico para insuficiência cardíaca sistólica crônica e as evidências disponíveis: uma revisão narrativa da literatura
CC Mizzaci, R Rieira, ALC Martimbianco - Diagn Tratamento, 2017 - docs.bvsalud.org
Introdução: A insuficiência cardíaca é uma síndrome clínica complexa de caráter sistêmico,
definida como disfunção cardíaca que ocasiona inadequado suprimento sanguíneo para …
definida como disfunção cardíaca que ocasiona inadequado suprimento sanguíneo para …
[HTML][HTML] Induction of Type 2 diabetes mellitus with antihypertensive therapy: is there any role of alpha adducin, ACE, and IRS-1 gene?
Hypertension and diabetes are related disorders that share common pathophysiological
pathways and occur together. Although hypertension itself is a risk factor for developing …
pathways and occur together. Although hypertension itself is a risk factor for developing …
The impact of cardiovascular drugs on glycemic control: a review
Objective: The prevalence of diabetes mellitus (DM) is steadily rising in the US, both in the
general population and among those with cardiovascular disease (CVD). Understanding …
general population and among those with cardiovascular disease (CVD). Understanding …
[HTML][HTML] How to improve adherence to life-saving heart failure treatments with potassium binders
M Lainscak - Cardiac Failure Review, 2017 - ncbi.nlm.nih.gov
Medications that affect the renin–angiotensin–aldosterone system (RAAS) form the mainstay
of current heart failure (HF) therapy in patients with reduced ejection fraction. Concerns …
of current heart failure (HF) therapy in patients with reduced ejection fraction. Concerns …